Skip to main content
PMC home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2015 Aug 8;31(4):491–504. doi: 10.1007/s12264-015-1546-4

Autophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice

He-Cheng Wang 1, Tao Zhang 1, Bolati Kuerban 1, Ying-Lan Jin 1, Weidong Le 2, Hideo Hara 3, Dong-Sheng Fan 4, Yan-Jiang Wang 5, Takeshi Tabira 6, De-Hua Chui 1,4,✉
PMCID: PMC5563717  PMID: 26254061

Abstract

The imbalance between ß-amyloid (Aß) generation and clearance plays a fundamental role in the pathogenesis of Alzheimer’s disease (AD). The sporadic form of AD is characterized by an overall impairment in Aß clearance. Immunotherapy targeting Aß clearance is believed to be a promising approach and is under active clinical investigation. Autophagy is a conserved pathway for degrading abnormal protein aggregates and is crucial for Aß clearance. We previously reported that oral vaccination with a recombinant AAV/Aß vaccine increased the clearance of Aß from the brain and improved cognitive ability in AD animal models, while the underlying mechanisms were not well understood. In this study, we first demonstrated that oral vaccination with rAAV/Aß decreased the p62 level and up-regulated the LC3B-II/LC3B-I ratio in APP/PS1 mouse brain, suggesting enhanced autophagy. Further, inhibition of the Akt/mTOR pathway may account for autophagy enhancement. We also found increased anti-Aß antibodies in the sera of APP/PS1 mice with oral vaccination, accompanied by elevation of complement factors C1q and C3 levels in the brain. Our results indicate that autophagy is closely involved in oral vaccination-induced Aß clearance, and modulating the autophagy pathway may be an important strategy for AD prevention and intervention.

Keywords: oral vaccination, autophagy, Akt/mTOR pathway, Aβ clearance, Alzheimer’s disease

Footnotes

These authors contributed equally to this work.

References

  • [1].Citron M. Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9:387–398. doi: 10.1038/nrd2896. [DOI] [PubMed] [Google Scholar]
  • [2].Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356. doi: 10.1126/science.1072994. [DOI] [PubMed] [Google Scholar]
  • [3].Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset alzheimer disease. Nat Rev Neurol. 2013;9:25–34. doi: 10.1038/nrneurol.2012.236. [DOI] [PubMed] [Google Scholar]
  • [4].Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330:1774. doi: 10.1126/science.1197623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–177. doi: 10.1038/22124. [DOI] [PubMed] [Google Scholar]
  • [6].Wisniewski T, Goni F. Immunotherapy for Alzheimer’s disease. Biochem Pharmacol. 2014;88:499–507. doi: 10.1016/j.bcp.2013.12.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7].Wisniewski T. Active immunotherapy for Alzheimer’s disease. Lancet Neurol. 2012;11:571–572. doi: 10.1016/S1474-4422(12)70136-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8].Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mildto- moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–333. doi: 10.1056/NEJMoa1304839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-tomoderate Alzheimer’s disease. N Engl J Med. 2014;370:311–321. doi: 10.1056/NEJMoa1312889. [DOI] [PubMed] [Google Scholar]
  • [10].Hara H, Monsonego A, Yuasa K, Adachi K, Xiao X, Takeda S, et al. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer’s disease. J Alzheimers Dis. 2004;6:483–488. doi: 10.3233/jad-2004-6504. [DOI] [PubMed] [Google Scholar]
  • [11].Mouri A, Noda Y, Hara H, Mizoguchi H, Tabira T, Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J. 2007;21:2135–2148. doi: 10.1096/fj.06-7685com. [DOI] [PubMed] [Google Scholar]
  • [12].Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol. 2014;112:24–49. doi: 10.1016/j.pneurobio.2013.10.004. [DOI] [PubMed] [Google Scholar]
  • [13].Wong Y C, Holzbaur EL. Autophagosome dynamics in neurodegeneration at a glance. J Cell Sci. 2015;128:1259–1267. doi: 10.1242/jcs.161216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].Chui DH, Tanahashi H, Ozawa K, Ikeda S, Checler F, Ueda O, et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med. 1999;5:560–564. doi: 10.1038/8438. [DOI] [PubMed] [Google Scholar]
  • [15].Steele J W, Gandy S. Latrepirdine (Dimebon(R)), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy. 2013;9:617–618. doi: 10.4161/auto.23487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Shibuya Y, Chang CC, Huang LH, Bryleva EY, Chang TY. Inhibiting ACAT1/SOAT1 in microglia stimulates autophagymediated lysosomal proteolysis and increases Abeta1-42 clearance. J Neurosci. 2014;34:14484–14501. doi: 10.1523/JNEUROSCI.2567-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].Kuballa P, Nolte WM, Castoreno AB, Xavier RJ. Autophagy and the immune system. Annu Rev Immunol. 2012;30:611–646. doi: 10.1146/annurev-immunol-020711-074948. [DOI] [PubMed] [Google Scholar]
  • [18].Saiga H, Nieuwenhuizen N, Gengenbacher M, Koehler A, Schuerer S M-, Alves P, et al. J Infect Dis. 2014. The recombinant BCG DeltaureC::hly vaccine targets the AIM2 inflammasome to induce autophagy and inflammation. [DOI] [PubMed] [Google Scholar]
  • [19].Jackson WT. Viruses and the autophagy pathway. Virology. 2015;479–480:450–456. doi: 10.1016/j.virol.2015.03.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20].Dong X, Tian W, Wang G, Dong Z, Shen W, Zheng G, et al. Establishment of an AAV reverse infection-based array. PLoS One. 2010;5:e13479. doi: 10.1371/journal.pone.0013479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21].Tong Y, Yang H, Tian X, Wang H, Zhou T, Zhang S, et al. High manganese, a risk for Alzheimer’s disease: high manganese induces amyloid-beta related cognitive impairment. J Alzheimers Dis. 2014;42:865–878. doi: 10.3233/JAD-140534. [DOI] [PubMed] [Google Scholar]
  • [22].Carrera I, Etcheverria I, Fernandez-Novoa L, Lombardi VR, Lakshmana MK, Cacabelos R, et al. A comparative evaluation of a novel vaccine in APP/PS1 mouse models of Alzheimer’s disease. Biomed Res Int. 2015;2015:807146. doi: 10.1155/2015/807146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23].Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van E LJ. Using mice to model Alzheimer’s dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet. 2014;5:88. doi: 10.3389/fgene.2014.00088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24].Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A. 2010;107:7036–7041. doi: 10.1073/pnas.1000645107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25].Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, et al. Mol Brain. 2014. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26].Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med. 1996;2:864–870. doi: 10.1038/nm0896-864. [DOI] [PubMed] [Google Scholar]
  • [27].Xian X, Liu T, Yu J, Wang Y, Miao Y, Zhang J, et al. Presynaptic defects underlying impaired learning and memory function in lipoprotein lipase-deficient mice. J Neurosci. 2009;29:4681–4685. doi: 10.1523/JNEUROSCI.0297-09.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [28].Yu Y, Zhou L, Sun M, Zhou T, Zhong K, Wang H, et al. Xylocoside G reduces amyloid-beta induced neurotoxicity by inhibiting NF-kappaB signaling pathway in neuronal cells. J Alzheimers Dis. 2012;30:263–275. doi: 10.3233/JAD-2012-110779. [DOI] [PubMed] [Google Scholar]
  • [29].Wisniewski T, Goni F. Immunotherapeutic approaches for Alzheimer’s disease. Neuron. 2015;85:1162–1176. doi: 10.1016/j.neuron.2014.12.064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Orsini F, DeBlasio D, Zangari R, Zanier ER, DeSimoni MG. Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front Cell Neurosci. 2014;8:380. doi: 10.3389/fncel.2014.00380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31].Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. 1982;57:239–242. doi: 10.1007/BF00685397. [DOI] [PubMed] [Google Scholar]
  • [32].Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. Mol Immunol. 2011;48:1592–1603. doi: 10.1016/j.molimm.2011.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33].Nilsson P, Saido TC. Dual roles for autophagy: degradation and secretion of Alzheimer’s disease Abeta peptide. Bioessays. 2014;36:570–578. doi: 10.1002/bies.201400002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [34].Tramutola A, Triplett JC, DiDomenico F, Niedowicz DM, Murphy MP, Coccia R, et al. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. J Neurochem. 2015;133:739–749. doi: 10.1111/jnc.13037. [DOI] [PubMed] [Google Scholar]
  • [35].Pujhari S, Kryworuchko M, Zakhartchouk AN. Role of phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) signalling pathways in porcine reproductive and respiratory syndrome virus (PRRSV) replication. Virus Res. 2014;194:138–144. doi: 10.1016/j.virusres.2014.09.017. [DOI] [PubMed] [Google Scholar]
  • [36].Jack C Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765–775. doi: 10.1002/ana.22628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [37].Hefti F, Goure WF, Jerecic J, Iverson KS, Walicke PA, Krafft GA. The case for soluble Abeta oligomers as a drug target in Alzheimer’s disease. Trends Pharmacol Sci. 2013;34:261–266. doi: 10.1016/j.tips.2013.03.002. [DOI] [PubMed] [Google Scholar]
  • [38].Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol. 2010;6:108–119. doi: 10.1038/nrneurol.2009.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [39].Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer’s disease. Neurobiol Dis. 2003;14:365–379. doi: 10.1016/j.nbd.2003.07.005. [DOI] [PubMed] [Google Scholar]
  • [40].Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G. Amyloid-based immunotherapy for Alzheimer’s disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol. 2014;10:405–419. doi: 10.1586/1744666X.2014.883921. [DOI] [PubMed] [Google Scholar]
  • [41].Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stuve O, Rosenberg RN. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA. 2009;302:1796–1802. doi: 10.1001/jama.2009.1547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [42].Faria AM, Weiner HL. Oral to lerance: mechanisms and therapeutic applications. Adv Immunol. 1999;73:153–264. doi: 10.1016/S0065-2776(08)60787-7. [DOI] [PubMed] [Google Scholar]
  • [43].Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS. Progress in the active immunotherapeutic approach to Alzheimer’s disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis. 2008;5:194–196. doi: 10.1159/000113700. [DOI] [PubMed] [Google Scholar]
  • [44].Wagner E, Frank MM. Therapeuti c potential of complement modulation. Nat Rev Drug Discov. 2010;9:43–56. doi: 10.1038/nrd3011. [DOI] [PubMed] [Google Scholar]
  • [45].Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164–1178. doi: 10.1016/j.cell.2007.10.036. [DOI] [PubMed] [Google Scholar]
  • [46].Aiyaz M, Lupton MK, Proitsi P, Powell JF, Lovestone S. Complement activation as a biomarker for Alzheimer’s disease. Immunobiology. 2012;217:204–215. doi: 10.1016/j.imbio.2011.07.023. [DOI] [PubMed] [Google Scholar]
  • [47].Benoit ME, Hernandez MX, Dinh ML, Benavente F, Vasquez O, Tenner AJ. C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloidbeta neurotoxicity. J Biol Chem. 2013;288:654–665. doi: 10.1074/jbc.M112.400168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [48].Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci. 2008;28:6333–6341. doi: 10.1523/JNEUROSCI.0829-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [49].Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice. Proc Natl Acad Sci U S A. 2002;99:10837–10842. doi: 10.1073/pnas.162350199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [50].Liu YH, Giunta B, Zhou HD, Tan J, Wang YJ. Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol. 2012;8:465–469. doi: 10.1038/nrneurol.2012.118. [DOI] [PubMed] [Google Scholar]
  • [51].Condello C, Yuan P, Schain A G d J. Nat Commun. 2015. Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [52].Zhang Y, Zou J, Yang J, Yao Z. 4Abeta 1-15-derived monoclonal antibody reduces more abeta burdens and neuroinflammation than homologous vaccine in APP/PS1 Mice. Curr Alzheimer Res. 2015;12:384–397. doi: 10.2174/1567205012666150325183708. [DOI] [PubMed] [Google Scholar]
  • [53].Guan X, Yang J, Gu H, Zou J, Yao Z. Im munotherapeutic efficiency of a tetravalent Abeta1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer’s disease. Hum Vaccin Immunother. 2013;9:1643–1653. doi: 10.4161/hv.24830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [54].Lee CY, Landreth GE. The role of microg lia in amyloid clearance from the AD brain. J Neural Transm. 2010;117:949–960. doi: 10.1007/s00702-010-0433-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [55].Prokop S, Miller KR, Heppner FL. Microgl ia actions in Alzheimer’s disease. Acta Neuropathol. 2013;126:461–477. doi: 10.1007/s00401-013-1182-x. [DOI] [PubMed] [Google Scholar]
  • [56].McGeer P M, Geer EG. The amyloid cascade -inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013;126:479–497. doi: 10.1007/s00401-013-1177-7. [DOI] [PubMed] [Google Scholar]
  • [57].Lionaki E, Markaki M, Tavernarakis N. Auto phagy and ageing: insights from invertebrate model organisms. Ageing Res Rev. 2013;12:413–428. doi: 10.1016/j.arr.2012.05.001. [DOI] [PubMed] [Google Scholar]
  • [58].Martinez-Vicente M, Cuervo AM. Autophagy an d neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol. 2007;6:352–361. doi: 10.1016/S1474-4422(07)70076-5. [DOI] [PubMed] [Google Scholar]
  • [59].Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005;64:113–122. doi: 10.1093/jnen/64.2.113. [DOI] [PubMed] [Google Scholar]
  • [60].Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J Neurosci. 2008;28:6926–6937. doi: 10.1523/JNEUROSCI.0800-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [61].Caccamo A, DePinto V, Messina A, Branca C O d S. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer’s disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J Neurosci. 2014;34:7988–7998. doi: 10.1523/JNEUROSCI.0777-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [62].Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8:445–544. doi: 10.4161/auto.19496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [63].Perluigi M, DiDomenico F, Butterfield DA. Neurobiol Dis. 2015. mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. [DOI] [PubMed] [Google Scholar]
  • [64].Heras-Sandoval D, Perez-Rojas JM, Hernandez-Damian J, Pedraza-Chaverri J. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal. 2014;26:2694–2701. doi: 10.1016/j.cellsig.2014.08.019. [DOI] [PubMed] [Google Scholar]
  • [65].Zhu Z, Yan J, Jiang W, Yao XG, Chen J, Chen L, et al. J Neurosci. 2013. Arctigenin effectively ameliorates memory impairment in Alzheimer’s disease model mice targeting both beta-amyloid production and clearance. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [66].Valdor R, Macian F. Autophagy and the regulation o f the immune response. Pharmacol Res. 2012;66:475–483. doi: 10.1016/j.phrs.2012.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [67].Chen M, Hong MJ, Sun H, Wang L, Shi X, Gilbert BE, et al. Essential role for autophagy in the maintenance of immunological memory against influenza infection. Nat Med. 2014;20:503–510. doi: 10.1038/nm.3521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [68].Puleston DJ, Zhang H, Powell TJ, Lipina E, Sims S P a I, et al. Elife. 2014. Autophagy is a critical regulator of memory CD8(+) T cell formation. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [69].Lin LT, Dawson PW, Richardson CD. Viral interactions with macroautophagy: a double-edged sword. Virology. 2010;402:1–10. doi: 10.1016/j.virol.2010.03.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [70].Jack C Jr, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen P S, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9:119–128. doi: 10.1016/S1474-4422(09)70299-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [71].Jack C, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–216. doi: 10.1016/S1474-4422(12)70291-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [72].Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71:505–508. doi: 10.1001/jamaneurol.2013.5847. [DOI] [PubMed] [Google Scholar]
  • [73].Lemere CA. Developing novel immunogens for a safe and ef fective Alzheimer’s disease vaccine. Prog Brain Res. 2009;175:83–93. doi: 10.1016/S0079-6123(09)17506-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [74].Sperling R, Mormino E, Johnson K. The evolution of precli nical Alzheimer’s disease: implications for prevention trials. Neuron. 2014;84:608–622. doi: 10.1016/j.neuron.2014.10.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [75].Yang C, Xiao S. New developments of clinical trial in immu notherapy for Alzheimer’s disease. Curr Pharm Biotechnol. 2015;16:484–491. doi: 10.2174/138920101606150407112319. [DOI] [PubMed] [Google Scholar]
  • [76].Herzog C. Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. Expert Rev Vaccines. 2014;13:399–415. doi: 10.1586/14760584.2014.883285. [DOI] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES